Gastroenterologie
a hepatologie

Treatment of complicated Crohn's disease with vedolizumab

Barbora Pipek¹, Přemysl Falt ^{Orcid.org  2}

+ Affiliation
¹ Centrum péče o zažívací trakt, Vítkovická nemocnice a. s., Ostrava
² II. interní klinika – gastroenterologická a geriatrická, LF UP a FN Olomouc

Summary

Crohn‘s disease is a chronic inflammatory disease of the digestive tract with an unclear etiology and severe exacerbations and complications in many patients. Vedolizumab is a monoclonal antibody against α4β7integrin receptors on the surface of activated leukocytes and is a relatively new biological treatment available in the Czech Republic since 2016. It has high selectivity for the gastrointestinal tract and prevents lymphocytes from moving from the capillary system into the gastrointestinal tract with a relatively low incidence of side effects. It is indicated for the treatment of adult patients with moderate to severe active Crohn’s disease and ulcerative colitis, who either do not tolerate or have inadequately responded or failed to respond to conventional therapy, such as anti-TNF therapy. We present a case report of a patient with a severe and complicated form of Crohn’s disease, in whom conventional treatments, such as steroid and anti-TNF therapy and surgical resection, failed, and who is now being successfully treated with vedolizumab. The patient’s clinical condition improved after vedolizumab treatment and corticosteroid therapy has stopped. Currently, the patient has been on vedolizumab for 1 year and shows deep remission of  the disease.

Keywords

Crohn’s disease, biodegradable stent, endoscopic stricture dilatation, ileocecal resection, vedolizumab

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Lukáš M. Vedolizumab v léčbě Crohnovy choroby. Gastroent Hepatol 2015; 69 (2): 146–150. doi: 10.14735/amgh2015146.
2. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68 (6): 481–484. doi: 10.14735/amgh2014481.
3. Falt P. Léčba vedolizumabem u pacientů s idiopatickými střevními záněty v České republice. Gastroent Hepatol 2017; 71 (1): 19–23. doi: 10.14735/amgh201719.
4. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintence therapy for Crohn’s disease. N Engl J Med 2013; 369 (8): 711–721. doi: 10.1056/NEJMoa1215739.
5. Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for pacients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147 (3): 618–627. doi: 10.1053/j.gastro.2014.05.008.
6. Lam MCW, Fu N, Bressler B et al. Vedolizumab for induction of remission in Crohn‘s disease in adults. A systematic review and meta analysis. JCC 2015: S227. Abstract P301.
7. Amiot A, Grimaud JC, Peyrin-Biroulet L et al. Effectiveness and safety of vedolizumab induction therapy for pacients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14 (11): 1593–1601. doi: 10.1016/j.cgh.2016.02.016.
8. Rejchrt S, Kopacova M, Brozik J et al. Biodegradable stents for treatment of benign stenoses of small and large intestines. Endoscopy 2011; 43 (10): 911–917. doi: 10.1055/s-0030-1256405.
9. Karstensen JG, Christensen KR, Brynskov J et al. Biodegradable stents for the tratment of bowel strictures in Crohn‘s disease: technical results and challenges. Endosc Int Open 2016; 4 (3): E296–E300. doi: 10.1055/s-0042-101940.